JP2019528038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528038A5 JP2019528038A5 JP2018563104A JP2018563104A JP2019528038A5 JP 2019528038 A5 JP2019528038 A5 JP 2019528038A5 JP 2018563104 A JP2018563104 A JP 2018563104A JP 2018563104 A JP2018563104 A JP 2018563104A JP 2019528038 A5 JP2019528038 A5 JP 2019528038A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- mab
- heavy chain
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 13
- 108010024164 HLA-G Antigens Proteins 0.000 description 10
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 5
- 238000010306 acid treatment Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101100007538 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cpc-1 gene Proteins 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031638A JP2022084670A (ja) | 2016-06-03 | 2022-03-02 | 抗ｈｌａ－ｇ特異的抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305650 | 2016-06-03 | ||
| EP16305650.0 | 2016-06-03 | ||
| PCT/EP2017/063503 WO2017207775A1 (en) | 2016-06-03 | 2017-06-02 | Anti hla-g specific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031638A Division JP2022084670A (ja) | 2016-06-03 | 2022-03-02 | 抗ｈｌａ－ｇ特異的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528038A JP2019528038A (ja) | 2019-10-10 |
| JP2019528038A5 true JP2019528038A5 (enExample) | 2020-06-18 |
| JP7034950B2 JP7034950B2 (ja) | 2022-03-14 |
Family
ID=56413601
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563104A Active JP7034950B2 (ja) | 2016-06-03 | 2017-06-02 | 抗ｈｌａ－ｇ特異的抗体 |
| JP2022031638A Pending JP2022084670A (ja) | 2016-06-03 | 2022-03-02 | 抗ｈｌａ－ｇ特異的抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031638A Pending JP2022084670A (ja) | 2016-06-03 | 2022-03-02 | 抗ｈｌａ－ｇ特異的抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190233520A1 (enExample) |
| EP (1) | EP3464364A1 (enExample) |
| JP (2) | JP7034950B2 (enExample) |
| KR (1) | KR102465491B1 (enExample) |
| CN (2) | CN109563169B (enExample) |
| AU (1) | AU2017272875B2 (enExample) |
| BR (1) | BR112018074847A2 (enExample) |
| CA (1) | CA3025681A1 (enExample) |
| EA (1) | EA201892793A1 (enExample) |
| IL (1) | IL263266B2 (enExample) |
| MX (1) | MX2018014979A (enExample) |
| NZ (2) | NZ748929A (enExample) |
| SG (2) | SG11201810149VA (enExample) |
| WO (1) | WO2017207775A1 (enExample) |
| ZA (1) | ZA201808332B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| CA3025681A1 (en) | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| LT3565579T (lt) | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| AR114789A1 (es) * | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| WO2020023268A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| SG11202101849XA (en) | 2018-08-31 | 2021-03-30 | Invectys SA | Chimeric antigen receptors against multiple hla-g isoforms |
| KR102867868B1 (ko) * | 2018-09-27 | 2025-10-13 | 티조나 테라퓨틱스 | 항-hla-g 항체들, 항-hla-g 항체들을 포함하는 조성물들 및 항-hla-g 항체들을 이용하는 방법들 |
| US20220281969A1 (en) * | 2019-08-14 | 2022-09-08 | Modmab Therapeutics Inc. | Antibodies that bind to lrp6 proteins and methods of use |
| KR20220088910A (ko) * | 2019-10-25 | 2022-06-28 | 인텔렉슨 게엠베하 | 치료 및 진단 표적으로서의 hla-h, hla-j, hla-l, hla-v 및 hla-y |
| CN113045656B (zh) * | 2020-07-27 | 2022-03-08 | 台州恩泽医疗中心(集团) | 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
| IL303656A (en) | 2020-12-17 | 2023-08-01 | Hoffmann La Roche | Anti-hla-g antibodies and use thereof |
| CN112794908A (zh) * | 2020-12-31 | 2021-05-14 | 杭州冰湖生物科技有限公司 | 一种抗hla-g抗体的制备及分析方法 |
| CN113278590A (zh) * | 2021-04-23 | 2021-08-20 | 台州恩泽医疗中心(集团) | 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用 |
| GB202111905D0 (en) * | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| CN115925930B (zh) * | 2021-11-04 | 2025-10-31 | 台州恩泽医疗中心(集团) | 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途 |
| CN114605543B (zh) * | 2021-12-17 | 2023-11-07 | 台州恩泽医疗中心(集团) | 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
| EP4473006A2 (en) | 2022-02-04 | 2024-12-11 | NKILT Therapeutics, Inc. | Chimeric ilt receptor compositions and methods |
| AU2023238458A1 (en) * | 2022-03-25 | 2024-10-17 | Hk Inno.N Corporation | Hla-g-specific antibody and use thereof |
| CN115819583A (zh) * | 2022-03-31 | 2023-03-21 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
| CN116284387B (zh) * | 2022-07-15 | 2025-10-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g2及hla-g6分子的单克隆抗体及用途 |
| CN117448412A (zh) * | 2022-07-26 | 2024-01-26 | 中山大学孙逸仙纪念医院 | CD158d分子、其中和抗体，及应用 |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN119080938B (zh) * | 2023-06-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒 |
| KR102793781B1 (ko) * | 2023-10-12 | 2025-04-14 | 주식회사 아이엠바이오로직스 | Hla-g에 특이적으로 결합하는 항체 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU696118B2 (en) * | 1995-04-07 | 1998-09-03 | Regents Of The University Of California, The | Antibodies for the detection of HLA-G |
| CN1312182C (zh) * | 2004-10-26 | 2007-04-25 | 四川新创生物科技有限公司 | 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
| WO2008121894A2 (en) * | 2007-03-30 | 2008-10-09 | Escape Therapeutics, Inc. | Endogenous expression of hla-g and/or hla-e by mesenchymal cells |
| EP2184070A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| EP2264067A1 (en) * | 2009-06-18 | 2010-12-22 | Hla-G Technologies | HLA-G alpha 1 multimers and pharmaceutical uses thereof |
| CN101967191A (zh) * | 2009-07-28 | 2011-02-09 | 广州天美生物技术有限公司 | Hla-g抗体制备方法及其在医学中的应用 |
| CN102086459A (zh) * | 2009-12-08 | 2011-06-08 | 华中科技大学 | 一种融合蛋白免疫抑制剂及其制备方法和应用 |
| US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| AU2016243128A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | HLA-G as a novel target for CAR T-cell immunotherapy |
| CA3025681A1 (en) | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
-
2017
- 2017-06-02 CA CA3025681A patent/CA3025681A1/en active Pending
- 2017-06-02 CN CN201780048691.4A patent/CN109563169B/zh active Active
- 2017-06-02 BR BR112018074847-1A patent/BR112018074847A2/pt unknown
- 2017-06-02 WO PCT/EP2017/063503 patent/WO2017207775A1/en not_active Ceased
- 2017-06-02 CN CN202210678074.5A patent/CN115286695A/zh active Pending
- 2017-06-02 EA EA201892793A patent/EA201892793A1/ru unknown
- 2017-06-02 NZ NZ748929A patent/NZ748929A/en unknown
- 2017-06-02 US US16/306,267 patent/US20190233520A1/en not_active Abandoned
- 2017-06-02 SG SG11201810149VA patent/SG11201810149VA/en unknown
- 2017-06-02 KR KR1020187037215A patent/KR102465491B1/ko active Active
- 2017-06-02 AU AU2017272875A patent/AU2017272875B2/en active Active
- 2017-06-02 JP JP2018563104A patent/JP7034950B2/ja active Active
- 2017-06-02 IL IL263266A patent/IL263266B2/en unknown
- 2017-06-02 MX MX2018014979A patent/MX2018014979A/es unknown
- 2017-06-02 SG SG10202107205VA patent/SG10202107205VA/en unknown
- 2017-06-02 NZ NZ788807A patent/NZ788807A/en unknown
- 2017-06-02 EP EP17728815.6A patent/EP3464364A1/en active Pending
-
2018
- 2018-12-10 ZA ZA2018/08332A patent/ZA201808332B/en unknown
-
2020
- 2020-10-26 US US17/080,017 patent/US11111302B2/en active Active
-
2021
- 2021-03-25 US US17/212,165 patent/US20210309748A1/en not_active Abandoned
- 2021-09-03 US US17/466,607 patent/US11312774B2/en active Active
-
2022
- 2022-03-02 JP JP2022031638A patent/JP2022084670A/ja active Pending
- 2022-04-25 US US17/728,483 patent/US11634494B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528038A5 (enExample) | ||
| JP2024038003A5 (enExample) | ||
| RU2505603C2 (ru) | Антитело против рецептора il-6 | |
| JP2019527553A5 (enExample) | ||
| JP2014221064A5 (enExample) | ||
| HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
| JP2017114866A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2019532619A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| ME03819B (me) | Antitela za icos | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2013538057A5 (enExample) | ||
| PL392809A1 (pl) | Przeciwciało monoklonalne przeciwko CD40 i jego część wiążąca antygen, zawierająca go kompozycja i jego zastosowanie, oraz linia komórkowa, cząsteczka kwasu nukleinowego, wektor komórka gospodarza i sposób wytwarzania | |
| HRP20221538T1 (hr) | Anti-transtiretinska antitijela | |
| JP2018510617A5 (enExample) | ||
| RU2018137110A (ru) | Антитела против psma и их применение | |
| JP2019523651A5 (enExample) | ||
| PH12022552520A1 (en) | Antibodies binding siglec15 and uses thereof | |
| JP2024029261A5 (enExample) | ||
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| PH12021551535A1 (en) | Monoclonal antibodies that bind specifically to human trbv9 |